http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
제약단지 인접 지역 지표수의 잔류 의약물질 생태위해성평가
박수현(Suhyun Park),강하병(Habyeong Kang),신혜수(Hyesoo Shin),유일한(Ilhan Ryoo),최경호(Kyungho Choi),고영림(Younglim Kho),박경화(Kyunghwa Park),김경태(Kyungtae Kim),지경희(Kyunghee Ji) 한국환경보건학회 2020 한국환경보건학회지 Vol.46 No.1
Objectives: Limited information is available on the presence and associated ecological risks of pharmaceutical residues in aquatic environments near pharmaceutical manufacturing areas in Korea. In this study, we investigated the current state of pharmaceutical contamination and its associated ecological risks in streams near a pharmaceutical manufacturing complex. Methods: Seven pharmaceuticals (acetaminophen, clarithromycin, diclofenac, diphenhydramine, ibuprofen, mefenamic acid and roxithromycin) were measured in water samples collected from the streams near a harmaceutical manufacturing complex. A predicted no-effect concentration (PNEC) was derived using either the assessment factor method or species sensitivity distribution method. In addition, a hazard quotient for each pharmaceutical was calculated by dividing its measured environmental concentration by its PNEC. Results: Samples collected downstream from the wastewater treatment plant (WWTP) had higher concentrations of pharmaceuticals than those collected from the reference site (upstream). Moreover, pharmaceutical concentrations were greater in ambient water than in the final effluent from the WWTP, which suggested that non-point sources were contributing to the contamination of the ambient water environment. Some of the target pharmaceuticals exhibited a hazard quotient >1, indicating that their potential ecological effects on the aquatic environment near the pharmaceutical industrial area should not be ignored. Conclusion: This study demonstrated that the pharmaceutical manufacturing area was contaminated with residual drugs, and that there was a possible non-point source near the WWTP effluent discharge area. The results of this study will aid in the development of management plans for pharmaceuticals, particularly in hotspots such as pharmaceutical industrial sites and their vicinities.
Design of HTS Toroidal Magnets for a 5 MJ SMES
Seyeon Lee,Kyung-Pyo Yi,Sang Ho Park,Ji-Kwang Lee,Woo-Seok Kim,Chan Park,Joon-Han Bae,Ki-Chul Seong,Ilhan Park,Kyeongdal Choi,Songyop Hahn IEEE 2012 IEEE transactions on applied superconductivity Vol.22 No.3
<P>A 2.5 MJ Superconducting Magnetic Energy Storage System (SMES) is being developed as a national R&D project in Korea. It is in 2nd phase of total 3 phases program. In phase 1, we developed a 600 kJ SMES which had the maximum storage over 1 MJ. Its magnet was an HTS solenoid, whereas the HTS magnet for phase 2 is a toroid which is composed of 28 HTS double pancake coils. The final target of phase 3 is to develop a 5 MJ SMES, which will start from next year. The operating temperature of the HTS magnet will be below 20 K by conduction cooling. In this paper, we present and compare conceptual designs of the magnet in the shape of toroid and the configuration of serial connection of two 2.5 MJ toroids. The most important design criterion is to minimize the total length of HTS conductors.</P>
Lim, Ilhan,Park, Joon Yeun,Kang, Hye Jin,Hwang, Jae Pil,Lee, Seung Sook,Kim, Kyeong Min,Choi, Tae Hyun,Yang, Sung Hyun,Kim, Byung Il,Choi, Chang Woon,Lim, Sang Moo S. Karger AG 2013 Acta haematologica Vol.130 No.2
<P>Abstract</P><P><B><I>Aims:</I></B> It was the aim of this paper to identify prognostic factors in patients with relapsed or refractory B-cell non-Hodgkin's lymphomas, treated by radioimmunotherapy (RIT) with radioiodinated human/murine chimeric anti-CD20 monoclonal antibody rituximab (<SUP>131</SUP>I-rituximab). <B><I>Methods:</I></B> Twenty-four patients were enrolled prospectively and were treated with unlabeled rituximab 70 mg and a therapeutic activity (median 7.3 GBq) of <SUP>131</SUP>I-rituximab. Contrast-enhanced <SUP>18</SUP>F-FDG PET/CT scans were performed before and after 1 month of RIT. Tumor sizes and maximum standardized uptake values (SUV<SUB>max</SUB>) of scans were measured. <B><I>Results:</I></B> Four of the 24 patients survived. High SUV<SUB>max</SUB> in a pretreatment scan was found to be related to poorer overall survival (OS) and progression-free survival (p = 0.04 and 0.02, respectively). Furthermore, a large tumor size in a pretreatment scan was associated with poorer OS but not with progression-free survival (p < 0.01 and p = 0.07, respectively). By multivariate analyses, a high SUV<SUB>max</SUB>, a large tumor size in a pretreatment scan and diffuse large B-cell lymphoma histology were significantly associated with poorer OS [p = 0.04/hazard ratio (HR) = 3.54, p < 0.01/HR = 5.52, and p = 0.02/HR = 3.38, respectively). <B><I>Conclusion: </I></B>SUV<SUB>max</SUB> and tumor size determined by a pretreatment <SUP>18</SUP>F-FDG PET/CT result as significant predictors of OS in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma treated by RIT.</P><P>Copyright © 2013 S. Karger AG, Basel</P>
Frontal Dysfunction Underlies Depression in Mild Cognitive Impairment: A FDG-PET Study
HyeSook Lee,IlHan Choo,DongYoung Lee,JeeWook Kim,EunHyun Seo,ShinGyeom Kim,ShinYoung Park,JiHye Shin,KiWoong Kim,JongInn Woo 대한신경정신의학회 2010 PSYCHIATRY INVESTIGATION Vol.7 No.3
Objective-Depression is a very common symptom in people with mild cognitive impairment (MCI), a preclinical stage of Alzheimer’s disease (AD), and in those with clinically evident AD. Moreover, MCI individuals with depression show a higher conversion rate to clinical AD than those without depression. This study aimed to elucidate the functional neuroanatomical substrate of depression in MCI. Methods-Thirty-six patients were recruited from a University Hospital-based cohort; 18 of these subjects had MCI with depression (MCI_D); the remaining 18 subjects were age- and gender-matched, and had MCI with no depression (MCI_ND). For comparison, 16 cognitively normal (CN) elderly individuals were also included. All subjects underwent Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) scanning and regional cerebral glucose metabolism was compared among the three groups by a voxel-based method. The relationship between severity of depression, as measured by Hamilton Rating Scale for Depression (HRSD) scores, and glucose metabolism was also investigated. Results-MCI_D showed lower glucose metabolism in the right superior frontal gyrus than MCI_ND. There was a significant negative correlation between HRSD score and glucose metabolism at the same frontal region for overall MCI subjects. When compared with CN, both MCI_D and MCI_ND showed decreased glucose metabolism in the precuneus, while MCI_D had, in addition, reduced metabolism in other diffuse brain regions. Conclusion-Given previous observations on depression in AD, our results suggest that functional disruption of the frontal region, known to be associated with primary or other secondary depression, underlies depression in preclinical AD as well as clinically evident AD.